Abstract
Medicare beneficiaries account for more than half of new cancer cases in the US annually, with cancer the leading cause of death in this population. Cancer detection at earlier stages with MCED testing along with standard of care (SoC) could improve survival outcomes and lower treatment costs, but is expected to increase screening costs. This modeling study explores key drivers of the potential range of VBP for MCED testing in a Medicare population.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
